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1. Introduction 
1.1 Background 
Although primary sclerosing cholangitis (PSC) is a fairly rare disease, it affects 
relatively young people and often implicates serious complications that have an 
impact on patient morbidity and mortality. Earlier studies of inflammatory bowel 
disease (IBD) in PSC have depicted that the characteristics of IBD in PSC differ from 
IBD unrelated to hepatobiliary disease regarding several aspects. However, previous 
studies display diverging results, probably due to differences in patient selection, size 
of the cohorts, study design and statistical methods used. To answer the unsolved 
questions regarding PSC-IBD, further studies are warranted. The high prevalence of 
PSC in the Nordic countries and the close collaboration between the Nordic liver 
transplant units through the Nordic Liver Transplant Registry have given our centre, 
as the only third-line PSC referral centre in Norway, an excellent opportunity to study 
various disease aspects of PSC and concomitant IBD in large patient cohorts.  
This thesis discusses various aspects of IBD in patients with PSC. The aims have 
been to describe the clinical features of IBD in PSC, with special emphasis on IBD 
disease activity and development of colorectal neoplasia, in both liver transplanted 
and non-transplanted patients.  
Firstly, an overview of PSC and IBD is given, including the characteristics of IBD in 
PSC, regarding in particular disease activity and development of colorectal neoplasia. 
Then, after accounting for the aims and the material and methods of the studies, a 
short summary of the results is given. The last part of the thesis aims at discussing 
the main results of the papers in a general context regarding both current knowledge 
and desirable future studies in the field of IBD in PSC. 
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1.2 Primary sclerosing cholangitis  
PSC is a chronic, cholestatic liver disease of largely unknown aetiology, 
characterized by inflammation and fibrosis of the biliary tree. Although the course is 
variable, it is frequently progressive, leading to end stage liver disease after a median 
of 10-15 years.1,2 The diagnosis is based on elevated cholestatic serum markers and 
characteristic cholangiographic findings on endoscopic retrograde cholangiography 
(ERC) or magnetic resonance cholangiography (MRC), consisting of multifocal 
strictures and dilatations of the intrahepatic and/or extrahepatic bile ducts.3 The 
median age at PSC diagnosis is 30-40 years, and approximately 2/3 of patients are 
male.1,2  The most common symptoms of PSC include abdominal pain, jaundice, 
pruritus, fatigue, fever, weight loss and eventually, symptoms of chronic cholestasis 
and portal hypertension.4 A majority of PSC patients have concomitant IBD, but a 
variety of other immune-mediated diseases, such as sarcoidosis, thyroid disease and 
diabetes mellitus type I are also overrepresented.5,6 There is also an increased risk of 
malignancy, especially in the biliary tree (cholangiocarcinoma), the liver (hepato-
cellular carcinoma), the large intestine (colorectal carcinoma) and the pancreas.7-10  
1.2.1 Epidemiology of PSC 
The reported incidence and prevalence rates of PSC vary widely, and incidence rates 
of 0-1.31 and prevalence rates 0-16.2 per 100.000 inhabitants have been described 
(table 1).11-20 Higher rates are reported among Northern European descendants than 
in Southern Europe and Asia, and the rates seem to be increasing.21 In Norway, the 
mean yearly incidence and the prevalence of PSC have been calculated to be 1.3 
and 8.5 per 100.000 inhabitants, respectively.14
1.2.2 Pathogenesis of PSC 
The pathogenetic mechanisms leading to inflammation and fibrosis with development 
of multiple strictures and dilatations of both intrahepatic and extrahepatic bile ducts in 
PSC are essentially unknown. At the stage when the diagnostic cholangiographic 
changes become evident, it is difficult to determine if observations represent primary 
disease mechanisms or secondary processes. A number of hypotheses on the 
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pathogenesis have been put forward, and several lines of research are currently 
pursued.22-24 The results of genetic studies in PSC must also be taken into account, 
since disease associated genes may give clues to pathogenetic pathways. 
Genetic susceptibility to PSC 
There is evidence of a genetic predisposition to PSC involving multiple genes, 
including both HLA- and non-HLA genes.25,26 Variants of these genes may contribute 
to the disease in combination with environmental factors and seem to mainly 
influence immunological processes. The importance of genetic factors in the etiology 
of PSC has been underscored by the finding in a large Swedish study that first-
degree relatives of PSC patients carry an increased risk of PSC.27 Siblings of PSC 
patients had a risk of developing PSC that was 9-39 times higher than that of the 
general population (relative sibling risk). Of note, siblings of PSC patients had an 
increased risk of developing ulcerative colitis (UC) (odds ratio (OR) 8.4, 95% 
confidence interval (CI) 4.1-17.3), which may indicate the presence of shared genetic 
susceptibility factors for PSC and UC. The strongest genetic associations in PSC 
have been detected in the HLA complex on chromosome 6.28,29 Most likely, both HLA 
class I and HLA class II genes are involved, but it has so far been difficult to define 
these associations precisely. By genome-wide association studies (GWAS) of a large 
number of PSC patients, several non-HLA susceptibility loci have also been 
identified.30,31 Some of these overlap with associations found in prototypical 
autoimmune diseases (IL2RA, IL2/IL21, MMEL1 and REL) and some with 
associations known from studies of IBD (3p21, 2q35, CARD9 and FUT2).25 The 
largest genetic study of PSC patients until now, including 3 789 PSC cases and 25 
079 controls, has revealed another 9 novel risk loci for PSC.32  
The “leaky gut” hypothesis                                                                                         
A hypothesis that directly links development of bile duct damage with the presence   
of an inflamed bowel would be attractive in PSC. The “leaky gut” hypothesis suggests 
that bacteria or bacterial components enter the portal venous system via an 
increased intestinal permeability caused by ongoing inflammation. Bacteria that in 
this way are translocated to the portal tracts in the liver, may subsequently stimulate 
the release of cytokines/chemokines and activate innate immune responses that lead 
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to cholangitis.23,24 This hypothesis has been supported by experiments in animal 
models. On the other hand, evidence of increased portal vein bacteremia in PSC-IBD 
patients is lacking. Antimicrobial treatment in PSC has not appeared to be effective in 
reducing disease progression,24 however, an improvement in serum alkaline 
phosphatase levels, the revised  Mayo Risk Score and liver histology  under 
treatment with metronidazole in combination with ursodeoxycholic acid (UDCA) has 
been noted.33 It can not be excluded that an infectious trigger is involved in PSC 
pathogenesis.23
The “gut lymphocyte homing” hypothesis 
This hypothesis also takes the interrelationship between PSC and IBD into account 
and could additionally explain that the course of PSC apparently runs independently 
of the IBD.34 It is proposed that memory T-lymphocytes generated in the inflamed gut 
persist in the enterohepatic circulation. Aberrant expression of the mucosal addressin 
cellular adhesion molecule 1 (MAdCAM-1) ligand on portal vein- and sinusoidal 
endothelium demonstrated in PSC livers, could recruit these lymphocytes by binding 
to their integrin Į4/ȕ7 receptor. In PSC there is also an aberrant expression in the 
liver of the chemokine ligand 25 (CCL25), which binds the chemokine receptor 9 
(CCR9) on memory T-lymphocytes and may support the recruitment of mucosal 
lymphocytes to the liver.35 Since MAdCAM-1 staining in portal veins has also been 
observed in other liver diseases, MAdCAM-1 expression might rather be secondary 
to chronic inflammation. 
The “autoimmune” hypothesis 
Several observations support the contention that autoimmune factors are involved in 
PSC pathogenesis. The strong HLA association is a typical trait of autoimmune 
disorders. A variety of autoantibodies have been detected,36 although none of these 
are PSC specific. Interestingly, the most frequent antibody in PSC (in up to 94% of 
cases) is a particular type of perinuclear anti-neutrophil cytoplasmic antibody 
(pANCA). pANCA is also frequently observed in UC and autoimmune hepatitis (AIH), 
suggesting common pathogenetic mechanisms. The concomitant diagnosis of other 
autoimmune disorders and the presence of features of AIH in some PSC patients 
also support a pathogenetic role for immunological factors. 
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The “toxic bile” hypothesis 
Bile acids may exert toxic effects, and several lines of evidence suggest that 
detrimental effects of bile acids also play a role in the development and progression 
of PSC. Mice that lack the phospholipid transporter multidrug resistance protein 2 
(mdr2) (abcb4 -/- mice) spontaneously develop severe PSC-like biliary fibrosis, 
initiated by bile leakage into the portal tracts.37 This protein corresponds to MDR3 
(ABCB4) in humans. Mutations in the ABCB4 gene in humans give rise to 
progressive familial intrahepatic cholestasis type 3 (PFIC3). Cholestatic liver disease 
has been observed in adults with certain ABCB4 mutations.38 Although ABCB4
mutations have not been associated with risk of PSC, particular ABCB4 variants may 
contribute to a more severe disease course in both PSC and primary biliary cirrhosis 
(PBC).23,39 Likewise, genetic variants of the steroid and xenobiotic receptor (SXR, 
also designated pregnane X receptor, PXR), a nuclear receptor involved in bile acid 
detoxification, are associated with a more aggressive disease course in PSC.40 The 
improvement of biochemical parameters of cholestasis by treatment with the bile acid 
UDCA also supports the concept of bile acid toxicity. 
The pathogenetic hypotheses are not mutually exclusive and at least some 
components of each of them may play a role at one or more stages of the disease 
progression in PSC. 
1.2.3 Clinical variants of PSC 
Small duct PSC  
The term small duct PSC designates a group of patients who present with a 
cholestatic biochemical profile along with clinical and histological features compatible 
with PSC, but who prove to have a normal cholangiogram.41 The definition of small 
duct PSC has varied in reports from different centers.18,42-45 Some reports have 
restricted a diagnosis of small duct PSC to patients with concomitant IBD, whereas 
IBD has been present in only a proportion (50-88%) of cases in other studies. In a 
population-based study from Canada including both adults and children, the 
diagnosis of large duct PSC occurred five times more frequently than small duct 
PSC, with annual incidence rates of 0.75/100.000 and 0.15/100.000, respectively.18
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In other reports, small duct PSC has been estimated to represent approximately 6–
11% of PSC patients.44,45 Small duct PSC appears to have a more favourable course 
than large duct PSC, with fewer patients progressing to end-stage liver disease and 
without a definite increased risk of cholangiocarcinoma. In a follow-up study of 83 
small duct PSC patients from three previous studies,43-45 19 (22.9%) patients 
progressed to large duct PSC in a median of 7.4 years.46 Only one patient developed 
cholangiocarcinoma, but this was after progression to large duct PSC. In comparison, 
cholangiocarcinoma was diagnosed in 19/157 (12%) in a matched group of patients 
with large duct PSC. Small duct PSC patients had a significantly longer liver 
transplantation-free survival compared with large duct cases. The differential 
diagnosis between small duct PSC and intrahepatic classic PSC, both progressing to 
liver cirrhosis, is a particular challenge. Treatment with UDCA (13–15 mg/kg/day) did 
not delay disease progression in a study including 30 treated and 7 untreated small 
duct PSC patients.47 Small duct PSC is considered a distinct clinical entity, different 
from large duct PSC,48 but it is also possible that the two conditions represent 
different aspects of the same disease spectrum. 
PSC-AIH “overlap” conditions 
It is a common clinical experience that some patients with PSC present with clinical, 
biochemical, serological and histological characteristics of both a cholestatic liver 
disease and AIH. These patients have cholangiographic findings qualifying for a 
diagnosis of PSC, but may concomitantly have relatively high serum 
aminotransferase activities, elevated immunoglobulin levels, positive autoantibody 
titres and histological interface hepatitis. This variant condition is often designated a 
PSC-AIH “overlap syndrome”.49-51 Internationally standardized criteria to define the 
PSC-AIH “overlap” condition and the corresponding PBC-AIH “overlap”, are lacking. 
In most reports, PSC-AIH “overlap” has been defined according to the original or 
revised International Autoimmune Hepatitis Group scoring system that originally were 
constructed for the diagnosis of AIH and not intended for defining “overlap” 
groups.52,53 In the largest among the series of PSC patients in which the frequency of 
PSC-AIH “overlap” has been studied, 7 – 14% of PSC patients scored for features of 
AIH.51  
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In some patients considered PSC-AIH “overlap”, the initial diagnosis has been AIH, 
often preceding the diagnosis of PSC by several years.54,55 It is relevant to suspect a 
diagnosis of PSC in AIH patients who have relatively marked cholestatic liver tests, 
histological evidence of bile duct injury or unsatisfactory response to 
immunosuppressive therapy, in particular if they also have IBD. Sequential 
development of features of AIH in patients with established PSC has been noted.54
Cases of overlapping AIH and small duct PSC have also been reported.56
There are several reports on the treatment of PSC-AIH “overlap” patients with 
corticosteroids with or without azathioprine, but no randomized, controlled clinical 
trials of therapy have been carried out. Both the European Association for the Study 
of the Liver (EASL) and the American Association for the Study of Liver Diseases 
(AASLD) recognize that the subgroup of PSC-AIH “overlap” patients may benefit from 
corticosteroids or other immunosuppressives, although the therapy is not evidence-
based.57,58 It is important that treatment is individualized and adjusted according to 
the response, with attention to side effects.51
IgG4-associated cholangitis 
The condition termed “IgG4-associated cholangitis” (IAC) is a biliary disease that 
presents with cholangiographic features similar to those of PSC.59,60 It is included in 
this context, since some IAC patients most likely have been classified as PSC. IAC is 
characterized by histological findings of dense lymphoplasmacytic infiltrates, fibrosis 
(often storiform in character) and obliterative phlebitis. The diagnosis requires an 
elevated IgG4+/IgG cell ratio by immunohistochemical staining of bile duct biopsies.61
IAC is also associated with elevated serum IgG4 levels, but levels may be normal at 
presentation and rather rise during follow-up.59 In a study including 53 cases of AIC, 
the sensitivity of serum IgG4 was 74%.62 Elevated levels of serum IgG4 were present 
in 9% among 127 PSC patients,63 however, no classical IAC could be identified in a 
study of 41 explanted PSC livers.64 In similarity with PSC, there is a male 
predominance in IAC. Age at presentation varies, but IAC patients generally are older 
at diagnosis that patients with classic PSC. In contrast to PSC, concomitant IBD is 
uncommon in IAC.62 The cholangiographical findings in IAC typically include distal 
bile duct stenosis, but proximal extrahepatic and intrahepatic bile ducts may also be 
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affected.62 IAC is frequently associated with pancreatic involvement with a diffuse 
enlargement or a pancreatic mass (autoimmune pancreatitis).59 IAC may also be 
associated with other fibrosing conditions. IAC is characterized by responsiveness to 
corticosteroid treatment that may result in resolution of symptoms and biochemical 
signs of cholestasis, reduction of serum IgG4 levels, as well as improvement or 
resolution of biliary strictures.57,59,60 It is therefore important to be aware of this 
condition. Algorithms for the diagnosis and management of suspected IAC have been 
proposed.57,62
1.2.4 Therapy of PSC 
Medical therapy 
There are several difficulties related to the development of effective medical therapy 
in PSC. Since the aetiology and pathogenesis remain essentially unknown, the 
design of targeted, causal therapeutic approaches is hampered.58,65-67 The apparent 
heterogeneity of the disease, the unpredictable disease course in the single patient, 
the overall slow disease progression and the relative scarcity of patients, are all 
factors that have contributed to make it difficult to perform sufficiently powered 
randomized, placebo-controlled clinical trials. There is currently no medical therapy 
that has been shown to definitely halt the disease progression in PSC.
Immunosuppressives and other agents. Several categories of drugs have been 
evaluated, including corticosteroids and other immunosuppressive agents 
(azathioprine, tacrolimus, ciclosporine A (CsA), methotrexate, mycophenolate mofetil 
(MMF)), TNF-Į-antagonists (pentoxiphylline, etanercept, infliximab), antifibrotics 
(penicillamine, colchicine, pirfenidone), antibiotics (minocycline) and a group of 
miscellaneous compounds (cladribine, nicotine, probiotics).67 None of these have 
proven to be effective in classical PSC, and several are associated with side effects. 
An exception applies to the subgroup of PSC patients who present with features of 
AIH who may benefit from immunosuppressive therapy.  
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Bile acids. The hydrophilic, dihydroxy bile acid, UDCA, is the drug that has been most 
extensively tested in PSC. Small pilot trials of UDCA showed improvement in 
biochemical parameters of cholestasis and liver histology using dosages of 10–15 
mg/kg/day.68,69 A larger, double-blind placebo-controlled trial in the US including 105 
patients and UDCA at a dosage of 13-15 mg/kg/day for 2 years, confirmed 
improvement in biochemistry, but did not find improvement of symptoms, histology or 
disease progression.70 In a Scandinavian randomized placebo-controlled study 
including 219 patients and UDCA dosage of 17-23 mg/kg/day for 5 years, there was 
a trend toward improved survival in the UDCA treated group, however, this did not 
reach statistical significance.71 A more recent randomized double-blind controlled trial 
carried out in the US, including 150 PSC patients and a high dosage of 28-30 
mg/kg/day of UDCA, was terminated because of an increased risk in the UDCA 
group for reaching the primary endpoints (death or liver transplantation (Ltx)).72 There 
was a higher risk of serious adverse events in the UDCA treated patients, despite 
overall biochemical improvement. The mechanism for the unexpected detrimental 
effect of UDCA is not evident. A potential beneficial effect of UDCA on the risk of 
cholangiocarcinoma has been suggested, but no significant effect on this risk has 
been demonstrated in double-blind placebo-controlled trials.71,72 Based on the sum of 
current evidence, international guidelines do not recommend a routine prescription of 
UDCA in PSC.57,58 24-norUDCA, in which the side chain is reduced by one carbon 
atom, has been effective in an animal model of PSC.73 Clinical studies of this 
compound are now in progress.  
Symptoms and complications of PSC (e.g. pruritus, bacterial cholangitis, metabolic 
bone disease, complications of liver cirrhosis and portal hypertension) should be 
treated according to guidelines.57,58
Endoscopic therapy  
Approximately 50% of PSC patients develop localized, high-grade strictures, so 
called “dominant” strictures during follow-up. These may cause symptoms of 
cholestasis and have a potential effect on prognosis. In an observational study, 
survival free of Ltx was significantly reduced in patients with a dominant stenosis 
(n=91) compared with those without (n=74) (p = 0.038).74 Endoscopic therapy is 
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commonly used to treat such strictures, but no randomized, controlled trials have 
evaluated the efficacy or optimal method.75 In any case, cholangiocarcinoma must be 
excluded, as far as possible. Both the EASL and the AASLD57,58 guidelines 
recommend that dominant strictures with significant cholestasis should be treated 
with biliary dilatation, with or without stenting. A stent should be placed in cases 
where dilatation is unsatisfactory. Prophylactic antibiotics during such procedures is 
recommended. There are, however, still some unresolved issues: Which is the best 
endoscopic approach? What is the optimal duration of stent placement? What is the 
optimal frequency of procedures? What are long-term results? A multicenter, 
prospective, randomized intervention trial to compare the efficacy of single session 
balloon dilatation and short-term stenting is now ongoing in the International PSC 
Study Group (http://www.ipscsg.org/). 
Liver transplantation  
Ltx is the only curative therapy for PSC. In the Nordic countries, PSC is a major 
cause of Ltx, constituting approximately 17% of all indications.76 Results of Ltx are 
favourable with 5-year survival rates close to 85%.67 Selection for and timing of Ltx is 
difficult due to the variable disease course and the frequent and unpredictable 
occurrence of hepatobiliary malignancies. Primarily, the indication for Ltx is liver 
failure with complications, similar to those for end-stage liver disease of other 
causes.58,67,77,78 PSC patients with liver cirrhosis are also at risk of developing 
hepatocellular carcinoma that may indicate transplantation in line with indications for 
other causes of this malignancy.58 PSC patients with recurrent, severe bacterial 
cholangitis, intractable pruritus or severely impaired quality of life due to fatigue, 
should also be considered for transplantation.
The presence of cholangiocarcinoma is usually considered a contraindication to Ltx 
due to poor results.78 In a previous study from the Nordic Liver Transplant Group, 17 
liver transplanted PSC patients proved to have cholangiocarcinoma, and for this 
group of patients the 5-year survival was 35%.79 This result may be improved by 
including patients with limited stage hilar tumors in a specific, extensive protocol 
comprising radiochemotherapy.58,80 PSC patients with biliary brush cytology 
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dysplasia may benefit from Ltx,81 and guidelines recommend that patients with 
evidence of cholangiocyte dysplasia are considered for Ltx.57
1.3 Inflammatory bowel disease  
IBD is characterized by a chronic, relapsing inflammation in the gastrointestinal tract. 
It can be divided into UC and Crohn’s disease (CD) based on clinical, endoscopic, 
histologic and radiological criteria.82 In approximately 10% of cases an overlapping 
pattern exists; these are categorised as IBD unclassified.83 UC is characterised by a 
uniform, diffuse mucosal inflammation, with a variable distribution from involvement 
limited to the rectum (proctitis) to total affection of the large intestine (total colitis). CD 
may occur in all parts of the gastrointestinal tract and involves the entire bowel wall. 
At endoscopy, the picture is dominated by rectal sparing, apthous ulcers, skip lesions 
(areas of inflammation alternating with normal mucosa), cobblestone pattern and 
longitudinal irregular ulcers.  
The most frequent symptom of UC is visible blood in the stools (>90%) with 
associated symptoms such as decrease in stool consistency, diarrhoea, abdominal 
pain, malaise, fever and weight-loss, depending on the severity and extension of the 
disease.84 The prognosis of UC is reported to be usually good during the first decade 
of disease with a low rate of colectomy (9.8%) and remission in most patients 
(55%).85 The disease is often (21-47%) associated with extra-intestinal 
manifestations, most commonly with affection of the eyes, joints, skin, liver and bile 
ducts.86 Whereas manifestations involving the skin, eyes and joints often parallel the 
disease activity in the gut, the hepatobiliary manifestations do not appear to 
correspond to the IBD activity.87
1.3.1 Epidemiology of IBD  
The incidence and prevalence of UC and CD are increasing and linked to 
westernised environment and lifestyle.88 The highest occurrence of IBD is reported in 
Northern Europe and North America. In a recent systematic review by Molodecky et 
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al., the annual incidence of UC and CD was found to be, respectively, 24.3 and 12.7 
per 100.000 person years in Europe, 19.2 and 20.2 in North America and 6.3 and 5.0 
in Asia and the Middle East (table 2).88 The highest reported prevalence values for 
UC and CD were found to be, respectively, 505 and 322 per 100.000 person years in 
Europe and 249 and 319 in North America (table 3).88
1.3.2 Pathogenesis of IBD  
IBD is precipitated by a complex interaction of environmental, genetic and 
immunoregulatory factors. Regardless of the underlying genetic predisposition, a 
growing body of data implicates a dysfunctional mucosal immune response to 
commensal bacteria in the pathogenesis of IBD, especially in CD. Possible triggers 
include a chronic inflammatory response precipitated by infection with a particular 
pathogen or virus or a defective mucosal barrier. The characteristic inflammatory 
response begins with an infiltration of neutrophils and macrophages, which then 
release chemokines and cytokines. These in turn exacerbate the dysfunctional 
immune response and activate either TH1 or TH2 cells in the gut mucosa, 
respectively associated with CD and, less conclusively, with UC. Elucidation of 
immunological and genetic factors indicate multiple points at which the inflammatory 
cascade may be interrupted, yielding the possibility of precise, targeted therapies for 
IBD.89
1.3.3 Colorectal dysplasia and cancer in IBD  
IBD patients with colonic inflammation have an increased risk of colorectal cancer.90
The magnitude of the risk, however, varies considerably in the literature and is a 
constant topic of debate.91,92 Some studies use data from tertiary referral centres or 
population-based studies, while others are based on small case series or individual 
case reports. The patients at greatest risk for the development of colorectal cancer 
are those with disease in the colon extending to the hepatic flexure or even more 
proximally (pancolitis). An overview of the factors associated with colorectal cancer in 
IBD is presented in figure 1.93  Approximately 8 to 10 years after the onset of 
symptoms, the risk of cancer begins to increase when compared to age-matched 
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controls.94-96 The approximate cumulative incidence of cancer is 5-10% after 20 years 
and 12-20% after 30 years of disease.94,96-98 In contrast, when colitis is limited to the 
left colon, most studies have found that the risk of developing colorectal cancer 
increases first after 15 to 20 years.99 Ulcerative proctitis likely does not place patients 
at greater risk for colorectal cancer.100 In a meta-analysis from 2001, comprising 116 
studies, Eaden et al. estimated the risk for cancer in patients with UC to be 
approximately 2% after 10 years, 8% after 20 years and 18% after 30 years of 
disease.90
Figure 1. Risk factors for development of colorectal cancer in IBD 
Like in other cancers, IBD-associated colorectal carcinogenesis is believed to follow 
a multistep process from inflamed, regenerative epithelium, to hyperplastic 
epithelium, to flat dysplasia and finally to invasive adenocarcinoma.101,102 The 
interaction of macrophages and neutrophils with the colonic epithelial cell plays a 
pivotal role in IBD-induced carcinogenesis. The interplay between reactive 
oxygen/nitrogen species overproduction, key arachidonic acid metabolites and 
cytokines/growth factors and activated inflammation-associated signal transduction 
pathways, along with immune system dysfunction, may contribute to the multistep 
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progression of IBD-associated carcinogenesis.103,104 Molecular alterations in IBD-
associated colon cancer, similar to sporadic colorectal cancer, include accumulation 
of gene mutations in tumor suppressor genes, oncogenes and DNA repair genes, as 
well as genomic instabilities such as aneuploidy, chromosome instability and 
microsatellite instability. Although similarities exist in the molecular pathogenesis of 
IBD-associated and sporadic colorectal cancer, there are also many differences, as 
illustrated by figure 2. The timing and frequency of the molecular genetic alterations 
are unique and are believed to result from different etiologic factors and cellular 
microenvironments. 
Figure 2. Carcinoma sequence pathway. (A) The IBD-associated carcinoma pathway with 
earliest identified molecular changes in p53, followed by chromosomal instability and finally 
ȕ-catenin/WNT signaling. (B) The adenoma-carcinoma sequence with a stepwise 
progression of mutational activation of oncogenes and inactivation of tumor suppressor 
genes, resulting in cancer. (Matkowskyj et al., Acta Pathol Lab Med 2013, with permission)101
1.3.4 Medical therapy of IBD  
Conventional medical therapies for UC and CD include aminosalicylates, 
corticosteroids, thiopurines, methotrexate and biologic compounds such as anti-
tumour necrosis factor agents, in addition to combinations with certain antibiotics. 
Although conventional drugs are the mainstay of current therapy in IBD, timely 
surgery must be considered. Algorithms for guidance of therapy have been 
suggested to provide optimal management of patients.105 The treatment algorithm for 
mild-to-moderately active UC is displayed in figure 3. 
25
                    
Figure 3. Management algorithm for mild-to-moderatly active UC. (Burger and Travis, 
Gastroenterology, 2011, with permission)105
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1.4 Characteristics of PSC-IBD  
1.4.1 General characteristics of PSC-IBD 
PSC is strongly associated with IBD, with a prevalence of IBD in PSC as high as 60-
80% in patients of Northern European descent whereas the prevalence has been 
found to be considerable lower (20-25%) in Asian studies (table 4).1-3,11,12,15,16,18-20,106-
125 UC accounts for the majority of cases (around 80%). Approximately 10% of cases 
are diagnosed with CD and 10% are classified as indeterminate colitis. Conversely, 
the reported prevalence of PSC is in the range 2-7.5% in UC patients and 1.4-3.4% 
in patients with CD (table 5). 86,116,126-136 IBD can develop both before and after 
diagnosis of PSC and also after Ltx (de novo IBD). The bowel disease is, however, 
most commonly diagnosed several years before PSC.137 Previous studies have 
suggested that IBD in PSC differs phenotypically from IBD unrelated to hepatobiliary 
disease regarding several aspects. PSC-IBD patients appear to have an increased 
incidence of pancolitis, rectal sparing and ileal involvement compared to IBD patients 
without hepatobiliary disease.138 In a case-control study, Loftus et al. found that 87% 
of the 71 PSC patients included had pancolitis compared to 54% in the control group 
consisting of 142 UC patients.138 The frequencies of rectal sparing and terminal ileitis 
were 52% and 51%, respectively, in the PSC patients compared to 6% and 7%, 
respectively, among the controls.138 IBD in PSC also seems to have a milder 
course.139 In addition, PSC-UC patients with an ileal pouch-anal anastomosis (IPAA) 
seem to be more prone to develop chronic pouchitis than UC patients without PSC 
(60% vs. 15%).140
Some of the genetic associations detected in PSC overlap with known associations in 
IBD, but there are also distinct differences that comprise both HLA- and non-HLA 
genes (figure 3).32,141 Among the 16 established PSC associated loci (counting 
several associations within the HLA region as one locus), only 8 also display 
significant association in IBD. Among the 163 currently known IBD associated loci, 
only 8 are significantly associated to PSC. 
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A majority of the performed clinical studies regarding IBD in PSC have important 
limitations with a limited number of patients included and a retrospective design. A 
larger, prospective study with a thorough assessment of the clinical features of IBD in 
PSC could therefore bring new insight in this field. 
  
                    
Figure 4. Venn diagram illustrating 163 IBD- and 16 PSC susceptibility loci and the overlap 
between them. Multiple associations within the HLA region are counted as one locus, both for 
PSC, ulcerative colitis and Crohn`s disease. 
1.4.2 Colorectal neoplasia in PSC-IBD 
Several studies have shown that PSC-IBD patients have a higher risk of colorectal 
malignancies than IBD patients without hepatobiliary disease,7,9,142-151 although these 
findings have not been universally agreed upon.10,152,153 In an early study, Broomé et 
al. matched 40 PSC-UC cases with 80 UC controls, where both groups were under 
endoscopic surveillance. The cumulative risk for colorectal neoplasia at 10, 20 and 
25 years after diagnosis of IBD was 9, 31 and 50%, respectively, in the PSC-UC 
group, compared to 2, 5 and 10%, respectively, in the control group.142 When Loftus 
et al. at the Mayo Clinic compared a group of 178 PSC-UC patients with the general 
population, a tenfold increase in risk of colorectal cancer (relative risk (RR) 10.3, CI 
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2.1-30) was displayed.152 However, no significantly elevated risk was found when 
compared to a population-based Swedish UC control group.152 Conversely, a 
metaanalysis from 2002 showed a fourfold increase in the risk of colorectal neoplasia 
in PSC-UC (OR 4.8, CI 3.6-6.4) when comparing 16.280 UC patients with 564 PSC-
UC patients.7  
PSC patients with CD are also found to have an increased risk of colorectal 
neoplasia. In a recent study, Lindström et al. showed that a study group of 28 PSC-
CD patients were more likely to develop colorectal neoplasia than a matched control 
group of 46 CD patients (OR 6.8, CI 1.65-27.9).154 On the contrary, Braden et al. did 
not find that the presence of PSC increased the risk of colorectal neoplasia in a group 
of patients with colonic CD.155  
Earlier studies have displayed some clinical characteristics regarding colorectal 
neoplasia that diverge between PSC-IBD and IBD patients. PSC patients tend to be 
younger at onset of IBD and at diagnosis of colorectal cancer.150,156 Yet, the time 
span between onset of IBD and colorectal cancer seems to be similar.145,156,157 The 
distribution of malignancy in the colon tends to be right-sided in PSC-IBD whereas it 
is shown to be more widespread in IBD.143,144,148,150,157 In one study from the 
Netherlands, IBD patients with colorectal cancer with and without PSC were 
compared and right-sided tumors were found to be more prevalent in the PSC group 
(67% vs. 36%). Additionally, tumors in patients with PSC were also found to be more 
advanced.157  
The diverging clinical characteristics between IBD patients with and without PSC may 
suggest a different colorectal carcinogenesis in PSC-IBD and IBD patients. The 
possible mechanisms behind this difference in cancer risk are, however, unclear. It 
has been speculated if PSC simply acts as a surrogate marker for a subclinical, long-
standing colonic inflammation.139,158 Interestingly, one study has recently shown an 
association between development of colorectal cancer (in addition to 
cholangiocarcinoma and gall bladder cancer) and a dominant bile duct stenosis in 
PSC patients with concomitant IBD.74 One hypothesis is that the tendency of right-
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sided colonic neoplasia in PSC-IBD could be due to alterations in the composition 
and concentration of the bile salt pool in PSC patients  that leads to a high 
concentration of toxic secondary bile acids in the colon.143,159 In both animal and 
human studies, exposure of cells of the gastrointestinal tract to high levels of bile 
acids has been shown to be an important risk factor for cancer.160 This theory has 
been supported by earlier studies of UDCA, indicating preventive effects on the 
development of colorectal cancers in PSC.161,162 On the other hand, the fact that PSC 
patients without IBD do not seem to have an increased risk of colorectal neoplasia 
suggests that other mechanisms (i.e. genetic factors) might play a role in the 
colorectal carcinogenesis.8  
1.5 Chemoprevention in PSC-IBD 
Although 5-aminosalicylic acid (5-ASA) and thiopurine analogues have been 
considered as potential chemopreventive agents against dysplasia and cancer in 
IBD, no agents have been shown to have indisputable chemopreventive activity in 
IBD. Steroids, folic acid and UDCA have been considered promising in a few 
population based, as well as in retrospective and in case control studies.163
1.5.1 5-ASA  
In addition to reduce inflammation, 5-ASA has been shown to decrease epithelial cell 
turnover and promote apoptosis in laboratory research. A metaanalysis including 9 
studies showed a protective association between the use of 5-ASA and colorectal 
neoplasia (OR 0.51).164 However, several of the studies included in this analysis lack 
statistical power since they have been predominantly observational, have included a 
small number of patients and have not taken into account important information 
regarding for example extent and duration of UC and use of concomitant medication. 
Later published, more robust studies have not shown the same degree of protective 
association of 5-ASA as previously described. The European Crohn’s and Colitis 
Organisation (ECCO) recommends however in their guidelines that all UC patients 
should be considered for chemopreventive treatment with 5-ASA.165
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1.5.2 UDCA 
A few retrospective studies have shown a potential chemopreventive effect of UDCA 
on colorectal neoplasia in PSC patients with IBD. In a study including 59 PSC 
patients with UC undergoing colonoscopic surveillance, patients receiving UDCA 
experienced a significantly reduced prevalence of colonic dysplasia, but the rate of 
dysplasia in the control group of this study was exceptionally high.162 In a follow-up of 
52 PSC patients with concomitant UC who participated in a placebo-controlled trial, 
UDCA (13-15 mg/kg/day) was also associated with a significantly reduced risk of 
developing colorectal dysplasia or cancer.161 Other the other hand, there are also 
studies that do not support a chemopreventive effect of UDCA on colorectal cancer. 
In a study comparing 28 PSC-UC patients receiving UDCA with 92 untreated 
patients, the cumulative incidence of dysplasia or cancer was not significantly 
different between cases and controls.159 In a retrospective analysis of the study of 
high-dose UDCA (28-30 mg/kg/day) mentioned above,72 the risk of colorectal 
neoplasia was even higher in the UDCA- than in the placebo group (hazard ratio 
(HR) 4.4, 95% CI 1.30-20.10, p = 0.02).166 Guidelines diverge in their 
recommendation regarding the use of UDCA as a chemoprophylactic agent. ECCO 
recommends the use of UDCA in PSC-IBD, the European guidelines suggest that 
UDCA should be considered in patients with a strong family history of colorectal 
cancer, previous colorectal neoplasia or longstanding extensive colitis, whereas the 
AASLD actually recommends against the use of UDCA  .57,58,165
1.6 Neoplasia surveillance in IBD and PSC-IBD 
Surveillance colonoscopy with multiple biopsies is recommended for all IBD patients 
at risk of developing colorectal neoplasia. The intensity of the program should, 
however, be dependent on the estimated risk in each individual patient. 
Nevertheless, it has not been proven in prospective studies that such a precaution 
increases survival.165,167  According to guidelines, a screening colonoscopy to 
reassess disease extent is recommended 8-10 years after onset of IBD.165 Four 
random biopsies every 10 cm of the colon should be performed and extra biopsies 
should be taken from abnormal areas. Chromoendoscopy with targeted biopsies of 
visible lesions has proven to be superior of random biopsies for detection of 
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neoplastic lesions.168 In high-risk patients (i.e extensive colitis) surveillance should 
start after the screening colonoscopy. In patients with moderate risk (i.e. left-sided or 
distal inflammation) the surveillance should start at a later stage, whereas patients 
without increased risk (proctitis) do not require further surveillance.165 If high-grade 
dysplasia (HGD) or adenocarcinoma is detected, a proctocolectomy should be 
performed. The further approach after the finding of low-grade dysplasia (LGD) 
regarding surgical treatment or more intensified surveillance should be individually 
tailored. In PSC, guidelines recommend full colonoscopy with biopsies at time of 
diagnosis, independently of IBD symptoms.58,165 After diagnosis of IBD, surveillance 
colonoscopy is recommended at 1-year to 2-year intervals.58,165 Some experts 
recommend a repeated colonoscopy after 4 years in PSC patients with a normal 
initial endoscopy, even if IBD symptoms are lacking.169  
1.7 PSC-IBD after liver transplantation 
1.7.1 Effect of Ltx on the clinical and endoscopic course of IBD 
One might anticipate that the clinical course of pre-existing IBD in PSC should 
improve after Ltx, given that some of the immunosuppressive drugs administered 
after Ltx are proven to be effective treatment of refractory IBD. Previous studies 
have, however, demonstrated conflicting results (table 6a).170-188 Some studies have 
depicted a mainly unchanged or improved course of IBD in PSC after Ltx,172,175,183
whereas others have found disease deterioration in a majority of patients.173,178,182,187  
In the largest study up to now, Dvorchik et al. showed an increased rate of colectomy 
due to active disease after Ltx compared to that before Ltx (HR 3.1, p = 0.001).178 In 
contrast, van de Vrie et al. showed no alteration of IBD after Ltx.175 Maclean et al. 
displayed highly variable IBD activity post Ltx with one third of patients experiencing 
an improved course, on third an unchanged course and one third a worsened 
course.179 The reasons behind the reported variable activity of IBD post Ltx are not 
clear. Some previous studies have shown that factors like younger age at IBD 
diagnosis, smoking at time of Ltx, use of tacrolimus and cytomegalovirus (CMV) 
infection post Ltx are associated with active inflammation post Ltx.173,177,180,188
Conversely, a combined HLA-DR and DQ disparity between donor and recipient, use 
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of 5-ASA, use of steroids and use of azathioprine alone or in combination with CsA 
and steroids have been shown to have a protective effect. 171,173,176,187 In cases of 
active IBD post Ltx, the course tends to be aggressive and induction and 
maintenance of remission can be very challenging.173,176,182
IBD can also occur de novo after Ltx (table 6b),170,173,175-177,182,187,188 and the annual 
incidence after solid organ transplantation has been shown to increase tenfold 
compared to the expected incidence in the general population.189 In PSC, the 
development of de novo IBD could, to some extent, be related to the expected 
incidence of naturally occurring IBD. De novo IBD tends to develop later in the course 
post Ltx compared to relapse of pre-existing IBD. In a study by Haagsma et al. the 
median time from Ltx to de novo IBD and to relapse of IBD was 3.9 years and 1 year 
(p = 0.045), respectively.173 The cumulative risk of de novo IBD 1, 3, 5 and 10 years 
post Ltx was 0, 4, 11 and 14%, respectively, and the risk of exacerbation of IBD  was 
20, 28, 39 and 39%, respectively.173  Promoting factors for development of de novo
IBD have been shown to be CMV infection, CMV mismatch between donor and 
recipient and use of tacrolimus.173,176,177 Use of azathioprine has shown protective 
effects.173 De novo IBD seems to respond better to medical therapy than relapsing 
IBD post Ltx.176,190  
1.7.2 Effect of Ltx on colonic neoplasia  
There has been a concern that Ltx could increase the risk of colorectal neoplasia due 
to the immunosuppressive treatment given.137,191 In contrast, it has also been 
speculated if Ltx could act as a protecting factor because of correction of cholestasis 
as a consequence of a normal functioning liver. Earlier studies have reported 
conflicting results regarding this issue (table 7).174,175,178,181,182,185,186,191-195 In a study 
by Loftus et al. the risk of colorectal carcinoma post Ltx was found to be increased 
fourfold, although not significantly so, compared to a historical cohort of non-
transplanted PSC-IBD patients.193 In contrast, a recent study from Cleveland, Ohio, 
displayed a similar rate of colorectal cancer when comparing liver transplanted and 
non-transplanted PSC-IBD patients.195 However, a higher rate of colorectal cancer 
was found post Ltx when comparing PSC and non-PSC patients,195 confirming the 
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results of a former study.194  In a study by Dvorchik et al., Ltx was not found to have 
any influence on the incidence of colorectal cancer in a cohort of 192 PSC-IBD 
cases.178 Earlier studies have found colorectal dysplasia, duration of IBD > 10 years 
and pancolitis to be risk factors for development of colorectal cancer post Ltx.194
Additionally, one study has shown CMV infection post Ltx to be a risk factor for 
colorectal dysplasia and cancer.195  
Due to small sample sizes, possible referral biases and discrepancy in study design 
and statistical methods used in earlier studies, the impact of Ltx on both the activity of 
IBD and the risk of colorectal malignancies in PSC-IBD post-transplant remains 
unsettled and calls for further studies. 
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2. Aims  
The aims of the present thesis were to study the characteristics of IBD in PSC, in 
particular the clinical disease activity and the development of colorectal neoplasia, 
both in liver transplanted and non-transplanted patients. The specific aims were: 
1. To describe the clinical, endoscopic and histopathologic features of IBD in a 
large, nationally centralised cohort of PSC patients. 
2. To assess the overall risk of colorectal neoplasia in PSC patients undergoing 
Ltx and to compare this risk before and after the transplantation. We also 
aimed to identify risk factors for the development of colorectal neoplasia post 
Ltx, in a longitudinal follow-up of a large Nordic PSC-IBD cohort undergoing 
Ltx. 
3. To describe the natural history of IBD in liver transplanted PSC patients by 
comparing the clinical course of IBD before and after Ltx and to identify factors 
associated with altered activity of IBD post Ltx, in a longitudinal follow-up of a 
large Nordic PSC-IBD cohort undergoing Ltx. 
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3. Material and methods  
3.1 Patient selection and design 
Paper I depicts the characteristics of IBD in a prospective, cross-sectional study in a 
nationally based cohort of PSC patients (n=184) admitted to the Medical Department, 
Oslo University Hospital, Rikshospitalet, between September 2005 and September 
2008.  Of these, 164 patients were consecutively included, whereas 20 liver 
transplanted patients were called upon since they were not scheduled for follow-up in 
the study period. The cause of referral was primarily related to the patients` liver 
disease, the majority being referred for either confirmation of diagnosis, management 
of PSC, or follow-up after Ltx. The patients underwent a clinical evaluation including 
ileocolonoscopy with assessment of segmental histopathology at inclusion. One 
investigator (KKJ) assessed the clinical data from the patient records, interviewed the 
patients and carried out the majority of the endoscopic examinations. The 
histopathologic evaluation was performed blindly according to a standardised 
protocol by an experienced pathologist (KG). Additionally, biopsies from 24 randomly 
selected study patients were evaluated independently by another, experienced 
pathologist (OPFC).  
In papers II and III the Nordic Liver Transplant Registry was used to identify all PSC 
patients (n=461) undergoing Ltx from November 1984 through December 2006 in 
Denmark (Copenhagen), Finland (Helsinki), Norway (Oslo) and Sweden 
(Gothenburg, Stockholm).76 With a retrospective, longitudinal study design, the 
characteristics of IBD regarding disease activity and development of colorectal 
neoplasia were described. Twenty-two patients were excluded due to lack of 
histopathologic confirmation of PSC in the explanted liver or loss to follow-up. All 439 
included patients were regularly followed up at the transplant centres. The medical 
records of the patients were reviewed by one experienced physician at each 
transplant centre. The patients were included at time of diagnosis of IBD and they 
were followed through Ltx until last clinical follow-up. Colorectal neoplasia and 
parameters regarding activity of IBD were recorded and the findings before and after 
Ltx were compared.
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3.2 Diagnostic criteria 
PSC was diagnosed according to accepted criteria, with typical findings of bile duct 
irregularities on cholangiography.3 In patients with normal cholangiography, small 
duct PSC was diagnosed based on the histopathologic findings in liver biopsies.46
The diagnosis of IBD was based on conventional clinical, endoscopic and 
histopathologic criteria.3,196-198  
3.3 Statistical analysis  
Data were described with proportions for categorical variables and median with range 
for continuous variables. Crude associations between categorical variables were 
assessed with Chi-square test or the Fisher’s exact test, when appropriate. 
Comparisons between groups with respect to continuous variables were performed 
using Mann-Whitney test. For comparison of dependent observations McNemars test 
was used. Crude patient survival after Ltx and cumulative risk of de novo IBD free 
survival were calculated using the Kaplan-Meier method and survival times were 
compared with the log-rank test. In paper I, Cohen’s kappa was used to investigate 
the reliability between the pathologists. A linear-by-linear trend test was used to see if 
there was a systematic change of segmental active inflammation from the caecum to 
the rectum. In papers II and III the possible effect of medication and other factors on 
the development of colorectal neoplasia and the course of IBD post Ltx were studied 
using a Cox proportional hazards model. Firstly, we fitted univariate models and 
secondly, we performed multivariate analyses. Since there was a potential difference 
in the detection rate of both activity of IBD and neoplasia given the selected centres, 
we stratified all analyses by centres. 
In paper II the cumulative risks of colorectal neoplasia in PSC-IBD patients both 
overall and before and after Ltx were estimated using competing risk regression 
analyses.199,200 The diagnosis of neoplasia was defined as the main event of interest 
and death and colectomy for other reasons than neoplasia were the competing 
events.199 For comparison purposes, a Cox model was used to calculate the 
cumulative hazard of neoplasia before and after Ltx. To investigate the effect of IBD 
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duration on the risk of neoplasia after Ltx, a competing risk regression model was 
fitted with neoplasia being the main event and death and colectomy for other reasons 
than neoplasia the competing events.  
In paper III the different outcomes in IBD activity post Ltx were presented as 
percentages with 95% CI. CI was constructed using the normal distribution 
approximation. The severity of IBD activity pre- and post Ltx in each patient and the 
relapse rate before and after Ltx were compared using Wilcoxon signed ranks test for 
paired data. The cumulative risks of colectomy due to refractory IBD before and after 
Ltx were estimated using competing risk regression analysis where colectomy for 
refractory IBD defined the main event of interest and colectomy due to other reasons 
and death were the competing events.199,200  
Due to the small number of CD patients included, a comparison between the IBD 
subgroups (CD and UC) with regard to risk of colorectal neoplasia154,155 and disease 
activity201,202 was not performed.   
P-values  0.05 were considered statistically significant. All statistical analyses were 
performed with SPSS version 18 and Stata version 11. 
3.4 Ethics 
In paper I the study was approved by the Regional Committee for Research Ethics in 
South Eastern Norway and the patients gave their informed consent. In paper II and 
III the studies were approved by the ethical committees in the respective countries. 
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4. Summary of the results 
Paper I 
In the included PSC cohort, 155 (84%) of 184 patients had IBD; 134 were initially 
diagnosed as UC, 15 as CD and six as IBD unclassified. In the liver transplanted 
group, colectomy had been performed in 15/60 (25%) patients (10 refractory disease, 
3 neoplasia, 1 both, 1 other). In the non-transplanted group, 24/95 (25%) patients 
had undergone colectomy (15 refractory disease, 6 neoplasia, 3 both). The patients 
with an intact colon and complete tissue samples (n=110) were further investigated. 
The median time since diagnosis of IBD was 11 (0-50) years. Forty-two (38%) 
patients had undergone Ltx with a median follow-up post Ltx of 3 (0-19) years. A 
majority (65%) of patients had a long-term clinical remission. Inflammatory findings 
were more frequent by histology than by endoscopy (89% vs. 47%, p<0.001). 
Histopathological signs of inflammation involved the right colon in 86% of patients 
and were purely right-sided in 23%. The general inflammatory activity was low, but 
higher in the right compared to the left colon (p<0.001). Terminal ileitis was present in 
20% (17/87) of patients and rectal sparing in 65% (70/107). The liver transplanted 
patients had lower clinical (p=0.035) and histological (p=0.013) IBD activity than the 
non-transplanted group. In conclusion, our findings support the hypothesis that PSC-
IBD may represent a distinct entity of colitis.  
Paper II 
Among the 439 PSC patients included, 353 (80%) had IBD at the time of Ltx and 15 
(3%) patients developed de novo IBD post Ltx. The median duration of IBD was 15 
(0-50) years at the time of Ltx and follow-up after Ltx was 5 (0-20) years. IBD was 
diagnosed before, simultaneously with and after PSC in 243 (66%), 43 (12%) and 82 
(22%) of patients, respectively. Ninety-one (25%) PSC-IBD patients developed 
colorectal neoplasia with a cumulative risk of neoplasia of 6.4% and 17%, 10 and 20 
years after diagnosis of IBD, respectively. The cumulative risk of colorectal neoplasia 
was higher after than before Ltx (HR 1.9, 95% CI 1.3-2.9, p=0.002). A multivariate 
analysis demonstrated aminosalicylates and UDCA to be significantly associated with 
an increased risk of colorectal neoplasia post Ltx (HR 2.6, 95%CI 1.0-6.6, p=0.041 
and 4.0, 95% CI 1.4-11.4, p=0.011, respectively). Neither duration nor activity of IBD 
was significant risk factors. Likewise, treated rejections and CMV infections did not 
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significantly contribute to an increased risk of colorectal neoplasia. The results 
underscore the importance of regular surveillance colonoscopies in PSC-IBD 
patients, also after Ltx. The novel association of aminosalicylates and UDCA to 
colorectal neoplasia in liver transplanted patients warrants further studies.  
Paper III 
The 218 among the 353 PSC-IBD patients who had an intact colon and had 
undergone pre- and post Ltx colonoscopies, were further characterized. Macroscopic 
colonic inflammation was more frequent after than before Ltx (153 vs. 124 patients, 
p<0.001). The degree of inflammation after Ltx was improved in 37 (17%), 
unchanged in 93 (43%) and worsened in 88 (40%) patients (p<0.001). The relapse 
rate after Ltx was higher than that before (p<0.001). The overall clinical IBD activity 
was also increased after Ltx (p<0.001). In addition, the cumulative risk of colectomy 
due to active disease after Ltx was increased compared to the corresponding risk 
before Ltx, although not reaching statistical significance (HR 1.4, 95% CI 0.4-1.2, 
p=0.22). Young age at diagnosis of IBD and dual treatment with tacrolimus and MMF 
were significant risk factors for worsened IBD activity post Ltx (HR 1.8, 95% CI 1.1-
2.9, p=0.011 and HR 3.9, 95% CI 1.9-7.9, p=0.001, respectively), whereas 
combination treatment with CsA and azathioprine showed a protective effect (HR 0.4, 
95% CI 0.2-0.9, p=0.043). Neither use of aminosalicylates, steroid- and 
antithymocyte globulin (ATG)/ muromonab-CD3 (OKT3) treated rejections nor treated 
CMV infections were significant risk factors. In conclusion, IBD activity in PSC-IBD 
patients increases after Ltx and appears to be related to the immunosuppressive 
regimen. CsA and azathioprine should be considered an alternative maintenance 
treatment in liver transplanted PSC patients.  
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5. Discussion 
This thesis describes the clinical characteristics of IBD in PSC, both in a national 
cohort (study I) and in a Nordic cohort of liver transplanted patients (studies II and III). 
In study I, we found that the majority of patients had a long term clinical remission of 
IBD. The histopathological signs of inflammation involved the right colon in the 
majority of cases and although the general inflammatory activity was low, it was 
higher in the right compared to the left colon. The overall IBD activity was lower in 
liver transplanted than in non-transplanted patients. In study II, we estimated the 
overall risk of colorectal neoplasia to be 6.4% and 17% at 10 and 20 years, 
respectively, after diagnosis of IBD. The risk was significantly higher after compared 
to before Ltx, also when taking duration of IBD into account. Aminosalicylates and 
UDCA were significantly associated with an increased risk of colorectal neoplasia 
post Ltx. Study III showed an increased inflammatory activity after compared to 
before Ltx regarding macroscopic colonic inflammation, relapse rate and overall 
clinical IBD activity. There was also a trend towards a higher risk of colectomy due to 
active IBD post- as compared with pre Ltx. Young age at diagnosis of IBD and dual 
treatment with tacrolimus and MMF were significant risk factors for increased IBD 
activity post Ltx, whereas combination treatment with CsA and azathioprine showed a 
protective effect.  
Our studies comprise the highest number of PSC patients included up to now in this 
field of research, both regarding the characterization of PSC-IBD and the comparison 
of IBD activity and risk of colorectal neoplasia before and after Ltx.  The results of the 
studies provide novel knowledge about IBD in PSC and raise new questions that call 
for future studies. 
5.1 Methodological considerations 
5.1.1 Patient selection 
In paper I, we included all PSC patients admitted to the Medical Department, Oslo 
University Hospital, Rikshospitalet, during a three year period. This study might be 
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regarded as population based since our centre has access to PSC patients from all 
over the country, being both the single transplant centre and the only third line PSC 
referral centre in Norway. However, we most likely do not see all of the patients with 
limited, uncomplicated PSC. In addition, the majority of patients are referred to us 
because of liver related- and not IBD related reasons. Even if a clear correlation 
between the severity of PSC and IBD is highly questionable,202-206 these factors might 
contribute to a referral bias. If taking into account the reported prevalence of PSC in 
Norway,14 our cohort constitutes almost half of the estimated number of present 
Norwegian PSC patients.  
In papers II and III, the Nordic Liver Transplant Registry was used to identify the liver 
transplanted PSC patients. This registry has been continuously updated since the 
first Ltx was performed in 1983 and it contains a complete survey of the Nordic liver 
transplanted patients. In these studies, the patient inclusion was almost complete, 
only 5% of patients were excluded (due to a lack of histopathologic confirmation of 
PSC in the explanted liver or loss to follow-up). All included patients had been 
regularly followed up and the clinical data were carefully recorded by experienced 
physicians at each transplant centre. Due to the high number of patients in the 
registry, the high inclusion rate and the completeness of data, we regard this cohort 
as highly representative of transplanted PSC patients. 
5.1.2 Design 
Paper I contains the first prospectively performed study with a systematic 
assessment of clinical, endoscopic and histopathologic characteristics of IBD in PSC. 
With the cross sectional design and the high number of patients included, we 
consider our results a valuable contribution to the existing literature on the 
characteristics of IBD in PSC. The most important limitation of the study is, however, 
the lack of a control group. The ideal control group would have been a population-
based UC cohort without hepatobiliary disease, matched for gender, age and disease 
duration and ongoing medication accounted for. Unfortunately, we were not able to 
include such patients in our study. As described above, the PSC patients are referred 
to our centre mainly due to the hepatobiliary disorder and not because of IBD issues. 
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The IBD cohort followed at our institution was regarded as unsuitable as a control 
group because of a high grade of selection due to our status as a third line referral 
center for patients with complicated IBD. Establishing a prospective population based 
control group at another institution was considered difficult because of a presumably 
long inclusion period and a time consuming and resource demanding study inclusion. 
Nevertheless, we regard the results of study I as valuable because it, with the cross 
sectional design, describes PSC-IBD patients as they present in clinical practice. 
Moreover, it is possible, to some extent, to compare these patients with published 
population based cohorts of IBD patients without hepatobiliary disease.85  
The approximately 3000 biopsies taken (four biopsies from each of the six colonic 
segments and four from the terminal ileum on each occasion) were assessed by one 
experienced pathologist (KG). Twenty-four (22%) of the 110 patients in the cohort 
were picked randomly and approximately 700 tissue samples were evaluated blindly 
by another experienced pathologist (OPFC). Based on former common practice, one 
fourth of the cohort was regarded as an adequate number for assessing interrater 
agreement. The percentage of agreement was calculated to evaluate the reliability of 
the interpretation of the histopathological evaluations. The detailed accordance 
regarding inflammatory changes in each recorded segment is displayed in table 8. 
The overall interrater agreement between the two pathologists was 70%, which is 
considered as good according to commonly used definitions.207 The agreement was 
highest in chronic active inflammation (90%) and lowest in goblet cell depletion 
(59%). Likewise, the accordance was highest in evaluating the terminal ileum (97%) 
and lowest in the cecum (38%). The reason for this variability is not quite clear. It can 
not be excluded that other factors besides direct interrater variations, like technical 
qualitites, changed rating conditions and day to day variation might be responsible for 
these differences. 
Papers II and III have a multicenter, retrospective, longitudinal, observational design. 
Due to the increased risk of colorectal neoplasia, all Nordic PSC patients undergo 
repeated colonoscopies and we assessed what we consider the most relevant 
colonoscopies relative to Ltx and the disease course post Ltx. We cannot rule out 
that inter- and/or intra-observer variability regarding the macro- and microscopic 
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evaluation of colonic inflammation and neoplasia might have influenced our results to 
some extent. This, together with the retrospective design, represents the most 
important weaknesses of the study. The strength of the study is the high and almost 
complete number of patients included. In addition, all patient data were recorded by 
only one investigator at each transplant centre. A prospective approach would have 
been the ideal design for investigating the aims of the study. A prospective study 
would, however, have been very challenging to conduct due to the low prevalence of 
liver transplanted PSC-IBD patients. 
In paper II, we included LGD as a neoplastic category in our analysis, in spite of well-
known reliability problems, such as sampling errors at endoscopy, inter-pathologist 
variation and the validity and specificity of dysplasia as a marker of neoplasia.93 We 
regard, however, LGD as an important entity because it represents the earliest 
recognizable histologic precursor of colorectal cancer known at present.208 Since 
colorectal cancer in PSC-IBD after all is a rare condition, the inclusion of LGD 
increased the number of events and made it feasible to utilize advanced statistical 
methodology to analyse the risk of neoplasia in the material.  
The assessment of increased risk of colorectal neoplasia after Ltx due to either 
duration of IBD or to other factors related to Ltx, represents a major methodological 
challenge in our study. However, both the competing risk analysis and the hazard 
ratio plot in study II displayed that IBD duration could not alone explain the increasing 
risk of colorectal neoplasia post Ltx. An exact estimation of the influence of disease 
duration versus Ltx on the risk of neoplasia was, however, not feasible in our study 
model. To analyse this further, a control group consisting of non-transplanted PSC-
IBD patients matched for IBD duration and age should have been included in the 
study. Such a patient cohort would, however, be very challenging to establish due to 
the low prevalence of PSC-IBD. 
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5.1.3 Statistics 
Competing risk regression analysis 
In study II, the most suitable statistical method for estimating the risk of colorectal 
neoplasia was found to be competing risk regression analysis because of the high 
frequency of informative censoring in the study sample. During the study, the patients 
were censored due to colectomy for non-neoplastic reasons or death, both events 
making it impossible to develop the event (neoplasia) at a later stage of the IBD 
disease. In contrast, if we used cause-specific Kaplan-Meier survival analysis, we 
would obtain a higher estimate of the cumulative incidence of the event of interest 
because all other events would be considered as censored. A major assumption of 
the Kaplan-Meier method is non-informative censoring which was not fulfilled in our 
sample. Our statistical method generated risk estimates generally lower than those 
previously reported, which is to be expected since cause-specific Kaplan-Meier 
estimates are always biased when informative censoring is present and by that tends 
to overestimate the risk.  
Uni- and multivariate analysis 
To test the possible effect of medication and other explanatory variables on the 
development of colorectal neoplasia (study II) and change in IBD activity (study III) 
post Ltx, we used a Cox proportional hazards model fitted firstly with one and then 
with several covariates. Since the number of possible variables to be tested is 
dependent on the sample size, we could only test a limited number of variables in our 
study and we chose the ones regarded most clinically relevant. We cannot exclude, 
however, that other untested or not recorded variables could possibly have an impact 
on the event. 
5.2 Characteristics of IBD in PSC 
In study I, our results were in accordance with the earlier findings of Loftus et al. 
regarding the distribution of colitis and the frequency of rectal sparing.138 We could 
not, however, confirm the high frequency of terminal ileitis in our study. Our finding of 
a 20% frequency of backwash ileitis is markedly lower than previously reported 
45
results. The discrepant findings may be partly explained by the varying criteria of 
classification regarding endoscopic and histologic features, a difference in ongoing 
medication and sample size of the studies. Loftus et al also found a significantly 
higher prevalence of terminal ileitis in PSC-IBD compared to the UC control group 
(51% vs. 7%).138 On the contrary, Joo et al. did not report any difference in the 
presence of backwash ileitis in 40 PSC-UC patients compared to 40 UC controls (36 
vs. 27%).209 The significance of terminal ileitis regarding symoms, severity of disease 
and prognosis in PSC-IBD is highly unclear. 
We also showed a relatively quiescent course of IBD in a majority of patients based 
on endoscopic data, calprotectin levels and the patient’s own opinion as assessed by 
the Simple Clinical Colitis Activity Index (SCCAI). This result is in consistency with 
the outcome of earlier, retrospective studies.139,144,210 In a Swedish case-control study 
for example, the PSC-IBD patients used less systemic steroids and were less 
hospitalized compared with the UC control group during 20 years of follow-up.139
Sokol et al. found that PSC-IBD patients required less immune-suppressors, less 
intestinal resections and had a lower cumulative colectomy rate than IBD patients 
without liver disease.144 In study I, the liver transplanted patients had a lower clinical 
and histological IBD activity compared to the non-transplanted group. The overall 
mean SCCAI score was, however, low (0.23) and in accordance with a slightly 
elevated median calprotectin level at 59 mg/kg (normal value <50). In accordance 
with the clinical and histological results, the calprotectin level was lower in the liver 
transplanted compared to the non-transplanted group, 46 (1-1945) vs. 61 (1-2844) 
mg/kg, but this difference was not significant (p=0.328). The lack of significance 
might be due to the overall low calprotecin level in both groups. Yet, to our 
knowledge, a study of the correlation between the activity of inflammation and the 
level of calprotectin in PSC-IBD has not been performed. 
Our novel finding of a higher degree of microscopic inflammation in the right 
compared to the left colon were in 2009, during preparation of our study results, 
verified in a retrospective study by Joo et al. who investigated the pathological 
findings of UC with and without PSC.209 In this study, the PSC-UC patients showed a 
higher degree of inflammatory activity in the cecum and a lower degree of activity in 
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the rectum compared with UC patients.209 Additionally, this study reported an overall 
lower grade of inflammation in PSC-IBD and neither the frequency of rectal sparing 
nor terminal ileitis were significantly higher in the study group compared to 
controls.209 Interestingly, two recent studies from Korea and Japan have displayed a 
similar disease pattern in PSC-IBD regarding pancolitis, right-sided predominance of 
inflammation, disease course and risk of colorectal neoplasia as shown in our and 
other Western studies.211,212  
In both the national and the Nordic cohorts of PSC patients, the diagnosis of IBD 
preceded that of PSC in the majority of cases (93/155 (60%) and 243/368 (66%), 
respectively). This is in accordance with previous findings.139,209  Due to the potential 
subclinical course of both PSC and IBD, the exact onset of the diseases is, however, 
difficult to ascertain. A recently published study by Sinakos et al. displays a shift in 
the timing of diagnosis of the two diseases, in that PSC in the recent years more 
often is diagnosed first, probably due to an increased use of MRC.213
In the national PSC cohort, 15 of 184 (8%) patients were initially diagnosed with CD 
and in the majority of patients, CD was diagnosed before PSC. The diagnosis of CD 
was in most cases established due to the colonic distribution of inflammatory 
findings. Very few patients had definite CD histopathology and none had small bowel 
affection, fistulas or strictures. These findings are in accordance with previous 
studies.106,131,138,154,201 In five of the 15 (33%) CD patients, there was a shift of 
diagnosis from CD to UC during the disease course. Hence, there seems to be a 
tendency to overdiagnose CD in PSC, probably due to the distribution pattern of the 
colonic inflammation, increased ileal affection and difficulties in the interpretation of 
subgroups of IBD in low grade colitis.  
At inclusion in study I, the study colonoscopy revealed significant neoplasia in four 
patients with IBD; two had a dysplasia-associated lesion or mass (DALM), one an 
adenocarcinoma and one a tubular adenoma. At diagnosis of neoplasia, the mean 
age was 54 years and the mean duration of IBD 17.4 was years. All lesions were 
localized proximally to the splenic flexure. At endoscopy, three out of the four patients 
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lacked active macroscopic colonic inflammation, whereas all patients had 
inflammatory changes by histology (data not shown in the article). None of the 
patients had undergone Ltx. These findings are in accordance with known risk factors 
for development of neoplasia in IBD, both regarding age, duration of IBD and 
presence of microscopic inflammation.93,214  
The results of this thesis further underscore the previous findings that IBD in PSC 
differs from IBD without liver disease regarding distribution and activity of colonic 
inflammation, severity of IBD symptoms and risk and distribution of colonic neoplasia. 
These phenotypic characteristics indicate that IBD in PSC might represent a distinct 
entity of colitis. Additionally, genetic studies have shown that HLA associations differ 
between PSC and UC patients whereas no significant differences are found between 
PSC patients with and without IBD.215 This supports the possibility that IBD in PSC 
may also differ from UC at a molecular level. 
5.3 Risk of colorectal neoplasia in PSC-IBD 
Several studies have shown that PSC patients with IBD have a higher risk of 
colorectal dysplasia and cancer than IBD patients without hepatobiliary disease,7,9,142-
144 but the reported magnitude of the risk varies considerably. Broomé et al. 
estimated the 20 year cumulative risk of colorectal neoplasia in PSC-IBD to be 
31%,142 whereas  the corresponding risk in our study was only 17%. In a more recent 
study, Claessen et al. found the risk of colorectal cancer in PSC-IBD after 10 and 20 
years to be 14% and 31%, respectively.9 Our lower risk estimates could be due to our 
use of competing risk analysis, as earlier accounted for (page 42), instead of the 
more widely used Kaplan-Meier survival analysis. Differences in study design and 
patient selection might also have influenced these results. 
We found a significantly higher risk of colorectal neoplasia after, as compared to 
before Ltx, also when taking duration of IBD into account. A high risk of colorectal 
neoplasia post Ltx in PSC patients has also been shown in earlier studies. Both Vera 
et al. and Hanouneh et al. found a higher risk of neoplasia after Ltx in PSC patients 
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compared to non-PSC patients.194,195 Loftus et al. displayed a fourfold, although not 
significant, increase in the risk of colorectal cancer, comparing liver transplanted PSC 
patients with a historical cohort of non-transplanted PSC patients.193 However, these 
studies are not directly comparable to our, since we estimated the risk of neoplasia in 
the same patients, before and after Ltx. On the contrary, in a study by Dvorchik et al. 
with a design similar to ours, PSC-IBD patients who underwent Ltx were followed and 
no difference in the risk of colorectal cancer before and after Ltx was shown.178 This 
study estimated the hazard rates by using Cox regression analysis and not 
competing risk as we did. Furthermore, it encompassed a considerably lower number 
of endpoints (n=19) than our study, as it reported no other neoplasias than colorectal 
cancer. These factors might explain the diverging outcomes. 
We consider our risk estimates of colorectal neoplasia after Ltx as conservative due 
to the use of competing risk regression analysis. They are also conservative in the 
sense that we chose to censor patients who received an ileo-rectal anastomosis due 
to active IBD, despite their continued risk of rectal neoplasia. 
Competing risk analysis was regarded as the most suitable statistical method 
because of the high frequency of informative censoring in the study sample.199,200 For 
comparison purposes, a Cox regression analysis was additionally performed, since 
this statistical method has been widely used in earlier studies.194,195 The HR for 
colectomy due to any type of neoplasia using competing risk and Cox regression 
analysis was 1.9 (p=0.002) and 4.2 (p<0.001), respectively.  For DALM, HGD and 
carcinoma combined, the HR using competing risk and Cox regression was 1.55 
(p=0.121) and 3.1 (p=0.001), respectively. These results further underscore that our 
risk estimates are more conservative than those of earlier studies. Yet, we regard the 
competing risk analysis as the most appropriate method in this setting. 
The mechanism behind the high risk of colorectal neoplasia in both transplanted and 
non-transplanted PSC-IBD patients is unclear. It has been hypothesized that 
alterations in the bile acids due to liver disease might have a carcinogenic effect on 
the proximal colon by an increased exposure of primary bile acids to intestinal 
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bacteria with a high rate of conversion of primary to carcinogenic secondary bile 
acids.143,160 This might explain both our and previous findings, although not 
universal,216 of a tendency to right-sided neoplasia in PSC-IBD.143,150,157 The 
predominantly right-sided inflammation, as demonstrated in paper I and in several 
other studies, 209,217,218 might also act as a factor predisposing for neoplasia in this 
region. The high risk might also be due to longstanding inflammation, as the 
histological signs of IBD in PSC can precede symptoms with many years,158 or it 
might be due to factors related to PSC itself. After Ltx, we cannot exclude the 
possibility that other untested or not recorded factors related to PSC or IBD, the 
transplantation procedure, or the course after Ltx could have an impact on the 
development of neoplasia. Likewise, the immunosuppressive regimen might play a 
role in the development of colonic neoplasia as displayed in earlier studies,219,220  
even though we found no significant association between these factors in our study.  
5.4 Chemoprevention in PSC-IBD 
Both 5-ASA and UDCA have been promoted as colorectal chemopreventive agents 
in IBD.161,162,164,165 In study III we found, rather surprisingly, that the use of these 
compounds in the liver transplanted PSC-IBD patients was associated with the 
development of colorectal neoplasia. A similar result, although not significant, was 
shown in a recent study; Hanouneh et al. included 43 liver transplanted PSC-IBD 
patients and demonstrated an association between 5-ASA and UDCA and post Ltx 
colonic neoplasia with HR of 3.3 and 2.7, respectively.195  
5.4.1 5-ASA 
In addition to its role as a therapeutic agent for mild to moderate UC, both preclinical 
and clinical studies have reported antineoplastic properties of 5-ASA,164,221-223
although the results have been conflicting.224,225 As earlier accounted for, a majority 
of the previous clinical studies have been observational with disparate methodologies 
and it has been frequently questioned whether the reported results are robust enough 
to answer the question of chemoprophylactic properties of 5-ASA. In a recent 
metaanalysis, including only non-referral populations and by that avoiding a referral 
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bias, Nguyen et al. did not find a protective effect of 5-ASA on colorectal cancer in 
IBD with a pooled, adjusted OR of 0.95 (95% CI 0.66-1.38).226 To our knowledge, no 
chemopreventive benefit of 5-ASA in PSC-IBD has been shown, neither in non-
transplanted nor in transplanted patients. In an earlier study, Sokol et al. compared 
PSC-IBD with IBD patients and found, despite lower colonic inflammation and a 
higher use of 5-ASA, a higher risk of colorectal cancer in the PSC-IBD patients.144
Likewise, in a Swedish study, Lindberg et al. found no significant effect of 
sulfasalazine on the rate of colorectal neoplasia in PSC-UC patients.150 In our study, 
a possible explanation for the result could be that the use of 5-ASA represents a 
surrogate marker for high inflammatory activity. However, when comparing patients 
with and without use of 5-ASA (data not shown in the article), we did not find any 
difference in the frequency of macro- and microscopic inflammation, neither at the 
pre Ltx nor the post Ltx colonoscopy. It can be speculated that our results reflect 
carcinogenic differences between IBD patients with and without PSC, resulting in a 
lack of colonic chemoprotective effect of 5-ASA in PSC-IBD.  
5.4.2 UDCA  
Our result, indicating that UDCA is associated with colorectal neoplasia in PSC-IBD 
patients post Ltx, is in conflict with two earlier studies that showed a protective effect 
of UDCA towards colorectal neoplasia. 161,162 However, several new studies support 
our finding.159,166,227,228 Lindström et al. recently found no difference in colorectal 
neoplasia-free survival between 48 UDCA-treated and 50 placebo-treated Nordic 
PSC-IBD patients with a total follow-up time of 760 years.227 In a study from the US, 
Eaton et al. reported an even higher risk of colorectal neoplasia in PSC-UC patients 
receiving UDCA at high doses compared to placebo-treated patients.166 Finally, in a 
recent metaanalysis including four studies and 281 patients, the use of UDCA did not 
appear to decrease the risk of adenomas or colonic cancer in PSC-IBD.228
Since neither UDCA nor 5-ASA seem to reliably reduce the elevated risk of colorectal 
neoplasia in PSC-IBD patients, we cannot recommend the use of these compounds 
for chemopreventive purposes post Ltx. 
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5.5 Surveillance of IBD in PSC 
It is well established that the cumulative risk of colorectal neoplasia in IBD increases 
with time.90 According to guidelines, all PSC patients should undergo a screening 
colonoscopy at diagnosis due to the high frequency of subclinical colitis in PSC,58,158
which is in accordance with the results of study I. Once IBD is confirmed, surveillance 
colonoscopy should be performed at 1- to 2-year intervals.57,58 This recommendation 
is in line with the findings of a recent study in which Thackeray et al. found that the 
risk of colonic neoplasia in PSC-IBD is similar for the periods 0-2 years and 8-10 
years after IBD diagnosis.216 Our finding of an even higher risk of colorectal neoplasia 
after Ltx, further underscores the importance of repeated surveillance colonoscopies 
in PSC-IBD, also after Ltx.  
5.6 De novo IBD 
The frequency and time of onset of de novo IBD post Ltx in our study is in 
consistency with earlier studies.173,176,188  Our findings of a decreased de novo IBD-
free survival in the group of patients receiving tacrolimus versus those who did not 
(p<0.001) and an increased de novo IBD free survival in the group receiving CsA 
versus those who did not (p<0.001) (data not shown in article), are also in 
accordance with previous results.173 Similarly, when performing a univariate Cox 
regression analysis, tacrolimus was associated with de novo IBD (HR 22, p=0.005), 
whereas CsA showed a protective effect (HR 0.5, p=0.005) (data not presented in 
article). Even if our study encompasses a limited number (n=11) of patients with de 
novo IBD, it represents, as far as we know, the largest cohort reported up to now. 
Due to the low prevalence of PSC, advanced statistics is very challenging to perform 
and our results should be interpreted with caution. However, the fact that 10 out of 11 
patients who developed de novo IBD received tacrolimus may suggest a role for this 
compound in the pathogenesis of IBD post Ltx.  
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5.7 Activity of IBD after liver transplantation 
Study III depicts an increased activity of IBD after Ltx, regarding colonic inflammation, 
number of relapses and overall IBD activity. Several earlier studies, with a variety of 
endpoints, study designs and statistical methods, have presented conflicting results 
related to this topic. Some have shown a mainly deteriorated IBD after 
Ltx,173,178,182,186,187,229 whereas others reveal an unchanged or improved IBD course 
post Ltx.172,175,183,184,203 In a recent study, based on the recordings of UC flares in 77 
PSC patients, Navaneethan et al. concluded that UC remains quiescent after Ltx.203
On the contrary, in a newly published study from Hungary, Gelley et al. demonstrated 
a significant increase in Mayo Disease Activity Index after Ltx in a cohort of 44 PSC-
UC patients.229  We consider our study results an important contribution to this field of 
research, due to the multicenter design, the large sample size, as well as the 
evaluation of IBD activity using multiple modalities. However, liver transplanted 
patients constitute a challenging subset of patients to follow up, given their medical 
complexity and immunocompromised status. Symptoms and clinical signs consistent 
with active IBD could possibly have other causes, such as side effects of medications 
(e.g. tacrolimus, MMF-colitis)230 and colonic infections (e.g. CMV and clostridium 
difficile colitis).231 In our study, these factors were excluded as far as possible by 
careful assessment of the patient records by experienced physicians at each 
transplant centre.  
Our finding of an increased IBD relapse rate after Ltx compared to before was based 
on six different predefined relapse criteria. In 80% of the recordings pre Ltx and in 
90% of those post Ltx, the identification of each relapse was based on the presence 
of two or more of the criteria. In 60% of cases, the recordings of IBD relapse post Ltx 
included an endoscopy (data not shown in article), which further strengthens the 
results.  
At the colonoscopies included in the study, both the macroscopic and microscopic 
findings pre- and post Ltx were recorded. We cannot exclude that the inclusion of 
microscopic data in our analysis could be useful, but we chose to use only the 
endoscopic recordings since these data were more complete than the reported 
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histology and because this modality traditionally has been regarded as the main tool 
to assess IBD activity. The multicenter design might represent a weakness of the 
study because of possible interobserver variability between the endoscopists 
performing the colonoscopies.
The tendency towards an increased risk of colectomy due to active disease post Ltx 
is in consistency with the earlier results of Dvorchik et al. who used a study design 
similar to ours.178 The reason why our result, as opposed to that of Dvorchik, did not 
reach significant value, might be the disparate statistical methods used, as we 
estimated the risk in a competing risk regression analysis whereas Dvorchik used the 
Cox regression analysis. Finally, we cannot exclude the possibility that other untested 
or not recorded factors related to PSC or IBD, the transplantation procedure or the 
course after Ltx, might have an impact on the level of IBD activity.  
In paper I, we concluded that the disease course was milder in the liver transplanted 
compared to the non-transplanted group. This might seem contradictory to the 
findings of increased inflammatory activity after Ltx in study III. The reason behind 
this could be the disparate study designs and patient selection. In paper I we 
compared the activity of IBD in two groups; the liver transplanted and the non-
transplanted patients. In this analysis, the patients who had undergone colectomy 
had been excluded due to the study design. Adversely, in paper III, when comparing 
the activity of IBD in each patient before and after Ltx, colectomy due to active 
disease post Ltx was taken into account. 
It might seem contradictory that dual treatment with tacrolimus and MMF was found 
to be associated with worsening of IBD post Ltx, since tacrolimus, and to some extent 
also MMF, are effective treatment options for IBD.232,233 Nevertheless, our study 
confirms the results by Verdonk et al. and Haagsma et al. that depict that the use of 
tacrolimus plays a role both in active IBD post Ltx and in the development of de novo
IBD.173,176 The reason behind these observations is not known. One theory is that the 
immune system reaches a new balance as a consequence of organ transplantation 
and that tacrolimus at some level interferes with the pathogenesis of IBD and 
54
enhances colonic inflammation.205 It is also difficult to determine to what extent MMF 
plays a role in the worsening of IBD post Ltx. The dose-related gastrointestinal 
toxicity linked to damage of enterocytes has over the last years become a well-known 
side effect of MMF and studies show that the histologic features of MMF-colitis in 
certain cases can mimic IBD colitis.230 Furthermore, we cannot exclude that the 
observation could be related to unidentified factors related to time, since a majority of 
patients used CsA before and a majority used tacrolimus after year 2000. However, 
neither patient follow-up, nor the endoscopic or histopathologic assessment and 
interpretation of the findings in IBD, have changed noteworthy during the study 
period. Likewise, there was not a significant difference in the number of patients that 
underwent Ltx due to end-stage liver disease before and after 2000 (p=0.061, data 
not shown in the article). Finally, we cannot exclude that a tendency to use higher 
dosage of the immunosuppressive compounds in earlier days might have affected 
the result.  
Both CsA and tacrolimus are calcineurine inhibitors and  effective immunosupres-
sants.234Although previous studies indicate some disparities regarding effects and 
side effects between CsA and tacrolimus,234 there is, to our knowledge, a lack of 
randomised studies demonstrating superiority for one compound over the other 
regarding i.e. rejection treatment or neurotoxicity. Based on the results of study III, 
we therefore recommend considering a shift from present standard maintenance 
treatment of tacrolimus and MMF to CsA and azathioprine in PSC patients 
undergoing Ltx, although an overall assessment of pros and cons must first be 
carried out. 
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6. Conclusions and future studies 
Study I is the first prospective study that clinically characterises IBD in the largest 
cohort of PSC patients up to now. It confirms previous findings of a high frequency of 
pancolitis, rectal sparing and a relatively quiescent course of IBD in PSC. Moreover, 
it displays the novel findings of a higher frequency of colonic inflammation by 
histology than by endoscopy and an isolated right-sided colitis in nearly 25% of 
cases. Additionally, with its cross-sectional design, a lower clinical and histologic IBD 
activity was found in the liver transplanted patients compared to the non-transplanted 
group. These phenotypic characteristics of IBD in PSC further support the hypothesis 
that PSC-IBD may represent a distinct entity of colitis. Newly developed methodology 
now enables characterisation of IBD in PSC also at a genetic, epigenetic and 
microbiotic level and this should be the aim of further studies. 
The findings of an increased risk of colorectal neoplasia and a higher IBD activity 
after compared to before Ltx, in a study of the hitherto largest cohort of PSC patients 
undergoing Ltx, confirms the results of some earlier, smaller studies. The increased 
risk of neoplasia post Ltx further supports the importance of repeated surveillance 
colonoscopies in PSC-IBD, also after Ltx. Our novel finding of an association 
between the use of UDCA and aminosalicylates and colorectal neoplasia post Ltx 
needs further verification. At present, we cannot recommend the use of these 
compounds for chemopreventive purposes post Ltx. Even though several theories 
exist, the cause behind the increased risk of colorectal neoplasia in PSC-IBD is still 
unknown. Future studies should focus on molecular mechanisms and other factors 
that contribute to the development of colorectal neoplasia in PSC-IBD. 
The finding that IBD activity post Ltx seems to be influenced by the 
immunosuppressive regimen given, warrants further studies. The aim of these 
studies should be to optimise and individually tailor the immunosuppressive therapy 
given after Ltx in PSC patients. 
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7. Appendix 
Table 1. Summary of studies reporting incidence and prevalence of PSC 
Reference Geographical 
region 
Study 
Period
Population No. of 
PSC 
patients 
Incidence, 
per 100 000/year 
(95% CI) 
Prevalence, 
per 100 000 
(95% CI) 
Escorsell   
et al.16  
Spain 1984-
1988 
19,230,000 43 0.07 0.22 
Boberg  
et al.14  
Oslo, 
Norway 
1986- 
1995 
130,000 17 1.31 (0.81- 2.10) 8.5 (2.8-14.2) 
Berdal   
et al.13
Akershus, 
Norway 
1985- 
1994 
180,000 12 0.7 5.6 
Hurlburt   
et al.17
Alaska, 
US 
1984- 
2000 
100,312 0 0 0 
Ang   
et al.11
Singapore 1989- 
1998 
750,000 10 NR 1.3 
Bambha  
et al.12
Olmsted County, 
Minnesota, US 
1976- 
2000 
NR 22 0.90 (0.56-1.36) 13.6 (7.1-20.1) 
Kingham   
et al.19
South Wales, 
UK 
1984- 
2003 
251,000 46 0.91 12.7 
Kaplan   
et al.18
Alberta, 
Canada 
2000- 
2005 
1,112,521 49 0.92 n.a. 
Card  
et al.15
UK 1987- 
2002 
2,027,909 223 0.41 (0.34-0.48) 3.85 (3.04- 4.80) 
Lindkvist  
et al.20
Västra Götaland, 
Sweden 
1992- 
2005 
1,492,000 199 1.22 16.2 
NR, not reported 
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Table 2. Summary of studies reporting incidence of UC and/or CD 
(Molodecky et al., Gastroenterology 2012, with permission)88
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Table 3. Summary of studies reporting prevalence of UC and/or CD 
(Molodecky et al., Gastroenterology 2012, with permission)88
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Table 4. Summary of studies reporting prevalence of IBD in PSC 
Reference Geographical 
region 
Study 
period 
No. of 
PSC 
patients 
Ulcerative 
colitis,  
no (%)ȕ  
Crohn`s 
disease, 
no (%)ȕ
Indeter-
minate 
colitis,  
n (%)ȕ
Total 
prevalence 
of IBD (%) 
Chapman  
et al.3
London,  
UK 
NR 29 21 (72) 0 - 21 (72) 
Wiesner   
et al.125
Minnesota,  
US 
1970- 
1977 
50 24 (48) 3 (6) - 27 (54) 
Sivak  
et al.120
Cleveland, 
Ohio, US 
1974-  
1978 
13 10 (77) 1 (8) 0 11 (85) 
Aadland   
et al.106
Oslo,  
Norway 
1975-  
1984 
45 37 (82) 6 (13) 2 (4) 45 (100) 
Helzberg   
et al.110
Connecticut, 
US 
1956 - 
1985 
53 31 (58) 2 (4) - 33 (62) 
Stockbrügger  
et al.121
Gothenburg, 
Sweden 
1975- 
1984 
46 36 (78) 2 (4) 5 (11) 43 (93) 
Wiesner   
et al.1
Minnesota,  
US 
1970- 
1984 
174 «Most 
commonly UC» 
- - 124 (71) 
Rabinovitz   
et al.118
Pennsylvania, 
US 
1985- 
1987 
66 39 (59) 8 (12) - 47 (71) 
Martin   
et al.113
Boston,  
US 
1950- 
1989 
178 70 (39) 15 (8) 3 (2) 88 (50) 
Farrant  
 et al.107  
London,  
UK 
1972- 
1989 
126 83 (66) 2 (2) - 85 (67) 
Schrumpf   
et al.119
Oslo,  
Norway 
1975- 
1989 
77 58 (75) 11 (14) 7 (9) 76 (98) 
Escorsell   
et al.16
Spain 1984- 
1988 
43 19 (44) 1 (2) - 20 (47) 
Wilschanski  
et al.124* 
Canada 1986- 
1994 
32 14 (44) 3 (9) - 17 (53) 
Lemmer   
et al.112
Cape Town, 
South Africa 
1981- 
1991 
36 20 (56) 2 (6) 4 (11) 26 (72) 
Broomé  
 et al.2
Sweden NR 305 220 (72) 20 (7) 9 (3) 249 (82) 
Kochhar   
et al.111
Chandigarh,  
India 
1984- 
1994 
18 9 (50)  0 0 9 (50) 
Okada  
et al.114
Japan NR 155 29 (19) 2 (1) 4 (3)# 35 (23) 
Okolicsanyi   
et al.115
Italy 1973-
1993 
117  42 (36) 12 (10) 9 (8) 63 (54) 
Takikawa  
et al.122
Japan 1975- 
1995 
192 38 (20) 2 (1) - 40 (21) 
Faubion Jr. 
et al.108* 
Minnesota,  
US 
1975- 
1999 
52 32/36 (89) §  4/36 (11)§ - 43 (83) 
Parlak  
et al.116
Turkey 1993- 
2000 
18 9 (50) 4 (22) - 13 (72) 
Ang   
et al.11
Singapore 1989- 
1998 
10 - 2 (20) - 2 (20) 
Ponsioen   
et al.117
The 
Netherlands 
1970- 
1999 
174 83 (48) 28 (16) 3 (2) 114 (66) 
Bambha   
et al.12
Olmsted Co., 
Minnesota, US 
1976- 
2000 
22 12 (55) 3 (14) 1 (5) 16 (73) 
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Feldstein   
et al.109* 
Minnesota,  
US 
1980- 
1999 
52 30 (58) 8 (15) 4 (8) 42 (81) 
Kingham 
 et al.19
South Wales, 
UK 
1984- 
2003 
53 30 (57) 3 (6) - 33 (62) 
Tischendorf   
et al.123
Hannover, 
Germany 
1978- 
2004 
273 141 (52) 29 (11) 2 (1) 172 (63) 
Kaplan   
et al.18
Alberta,  
Canada 
2000- 
2005 
49 14 (29) 19 (39) - 33 (67) 
Card  
et al.15  
UK 1987- 
2002 
223 67 (30) 13 (6) 28 (13) 108 (48) 
Lindkvist  
et al.20
Västra Göta-
land, Sweden 
1992 - 
2005 
199 129 (65) 17 (9) 5 (3) 152 (76) 
ȕof all study patients, *pediatric study,  #designated “Other type of colitis” in the publication, §with sufficient 
diagnostic evaluation, NR, not reported 
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Table 5. Summary of studies reporting prevalence of PSC in IBD 
Reference Geographical 
region 
Study 
period 
No. of IBD 
patients 
No. (%) of PSC patients 
Schrumpf   
et al.129  
Oslo,  
Norway 
1974-1978 336 (UC) 14 (4.2)* 
Shepherd  
et al.132
Oxford,  
UK  
NR 681 (UC) 17 (2.5) 
Lupinetti  
 et al.134
Baltimore, 
Maryland, US 
1966-1977 202 2 (1.0) 
Tobias   
et al.135  
South Africa 1975-1981 250 (UC) 
164 (CD) 
8 (3.2)  
2 (1.2)  
Monsén   
et al.127
Stockholm,  
Sweden 
1955-1979 1274 (UC) 13 (1.0) ȕ  
Olsson 
et al.128
Sweden  1988 1500 (UC) 55 (3.7) 
Wewer   
et al.130
Herlev,  
Denmark 
NR 396 (UC) 
125 (CD) 
3 (0.8) 
0 
Broomé  
et al.133
Stockholm,  
Sweden 
1955-1979 1274 (UC) 29 (2.3) 
Rasmussen   
et al.136
Aalborg,  
Denmark 
1976-1987 305 (UC) 11 (3.6) 
Rasmussen   
et al.131
Aalborg,  
Denmark 
1976-1991 262 (CD) 9 (3.4) 
Bernstein   
et al.86
Manitoba,  
Canada 
1984 -1996 4454 (IBD) UC: males 3%, females 1% 
CD: males 0.4%, females 0.3%
Parlak   
et al.116
Turkey 1993-2000 386 (UC) 
110 (CD) 
9 (2.3) 
4 (3.6) 
Mendes  
et al.126
Rochester, 
Minnesota, US 
2000-2001 544  25 (4.6) 
*later follow-up: 25 (7.5%)23536, ȕincluding 11 patients with pericholangitis, UC, ulcerative colitis; CD, Crohn`s 
disease; NR, not reported 
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Table 6a. Summary of studies reporting IBD activity after liver transplantation in PSC patients 
Reference Study 
period 
No. of 
PSC-IBD 
patients#
Median 
follow-up 
post Ltx, yrs 
Course of IBD post Ltx, 
promoting and protecting factors  
for increased IBD activity post Ltx 
Gavaler  
et al.172
1982-
1985 
23 1.9ȕ 14 better, 9 unchanged, 0 worse 
Shaked  
et al.174
1985-
1990 
24 2.5ȕ 4 better, 12 unchanged, 8 worse 
Stephens  
et al.184
1985-
1991 
27 NR 18 better, 4 unchanged, 5 worse 
Knechtle  
et al.185
1986-
1994 
21 NR 7/21 (33%) active IBD 
Miki  
et al.180
1982-
1992 
26 NR 9/26 (35%) active IBD 
Promoting: Younger age at IBD diagnosis 
Narumi  
et al.181
1988-
1993 
24 3 6/19 (32%) progressive IBD 
Papatheo-
doridis  
et al.182
1989-
1996 
16 3.2 0 better, 8 unchanged, 8 worse 
Befeler  
et al.170
1985-
1996 
23 3.1ȕ 11 better, 12 unchanged, 0 worse 
Saldeen  
et al.183
NR 17 4ȕ 10 better, 6 unchanged, 1 worse 
Dvorchik  
et al.178
1981-
1997 
206 5.9ȕ Increased colectomy rate due to active IBD 
Maclean  
et al.179
1985-
2000 
44 6.1ȕ 14 better, 16 unchanged, 14 worse 
Van de Vrie  
et al.175
1987-
2000 
17 5 2 better, 12 unchanged, 3 worse 
Haagsma  
et al.173
1979-
2001 25* 7.2 
9/25 (36%) active IBD 
Promoting: pre Ltx IBD, use of TL
Protecting: use of Azt, use of CsA/Azt/CS 
Ho  
et al.186
1992-
2003 
26 4.4 Higher CS requirement rate post Ltx  
Higher IBD relapse rate post Ltx 
Verdonk  
et al.177
1987-
2002 
31* NR 12/31 (39%) active IBD 
Promoting: CMV infection 
Verdonk  
et al.176
1994-
2004 
49* 6.1 32/49 (65%) active IBD 
Promoting: IBD symptoms at time of Ltx, short 
interval of IBD before Ltx, use of TL  
Protecting: use of 5-ASA
Cholongitas   
et al.171
1989-
2004 
33 2.8 0 improved, 16 unchanged, 17 worse 
Protecting: combined HLA-DR and -DQ disparity 
between donor and recipient
Moncrief  
et al.187
1989-
2006 
49 5.7 3 better, 33 unchanged, 13 worse$
Protecting: longer use of CS 
Joshi   
et al.188
1990-
2009 
74 6.6ȕ 33/74 (45%) flare (active IBD) 
Promoting: smoking at time of Ltx 
#with intact colon at time of Ltx, ȕmean, *PSC and autoimmune hepatitis patients, $5 de novo IBD included, 
NR, not reported; TL, tacrolimus; Azt, azathioprine; CsA, Ciclosporine A: CS, corticosteroids 
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Table 6b. Summary of studies reporting de novo IBD in PSC 
  
Reference Study 
period 
Median  
follow-up 
post Ltx, 
yrs 
Prevalence, 
n (%) 
Time Ltx –  
de novo IBD,  
median, yrs 
Cumulative incidence, promoting  
and protecting factors for de novo  
IBD post Ltx 
Papatheo- 
doridis        
et al.182
1989-
1996 
3.2 3/12 (25) 2ȕ NR 
Befeler   
et al.17072 
1985-
1996 
3.1¥ 1/6 (17) NR NR 
Haagsma  
et al.173
1979-
2001 
7.2 6/53 (11)* 3.9 Cum. ins. at 1, 3, 5, 10 yrs: 0, 4, 11, 14%        
Promoting: use of TL 
Protecting: use of Azt, use of CsA/Azt/CS
5/6 de novo patients used TL  
Van de Vrie  
et al.175
1987-
2000 
5 1/11 (9) 0.8 NR 
Verdonk   
et al.177
1987-
2002 
6.4 6/53 (11)* NR Promoting: CMV infection
6/6 de novo patients experienced CMV 
infection 
Verdonk   
et al.176
1994-
2004 
6.1 8/42 (19)* 5.2 Cum. ins. at 1, 3, 5, 10 yrs: 0, 5, 10, 30% 
Promoting: CMV mismatch, use of TL (NS) 
Protecting: Azt (NS) 
Moncrief   
et al.187
1989-
2006 
5.7 5/17 (29) 4.8 NR 
Joshi  
et al.188
1990-
2009 
6.6 6/36 (17) 2.4ȕ Cum. incidence at 1, 5, 10 yrs: 7, 22, 29% 
6/6 de novo patients used TL 
*PSC and autoimmune hepatitis patients, ȕmean, NR, not reported; NS, not significant; TL, tacrolimus; Azt, 
azathioprine; CsA, Ciclosporine A 
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Table 7. Summary of studies reporting colorectal neoplasia in PSC-IBD after liver transplantation 
Reference No. of PSC- 
IBD patients#
Median 
follow-up 
post Ltx, yrs
Prevalence of, cumulative risks and  
risk factors for colorectal neoplasia post Ltx 
Higashi  
et al.191
36 3.8 2 (2 CRC)  
Shaked  
et al.174
29 2.5ȕ 0 
Bleaday  
et al.192
27 3.3ȕ  3 (2 CRC, 1 villous adenoma with severe dysplasia) 
Knechtle  
et al.185
21 NR 3 CRC  
Narumi  
et al.181
22 3.1 4 (3 CRC (2 recurrent), 1 CR dysplasia) 
Loftus  
et al.193
57  4.2 3 CRC. Cum. risk for CR dysplasia 5, 8 yrs post Ltx: 15, 21% 
Increased risk of CRC post Ltx but NS compared to non-
transplanted PSC-IBD patients (RR 4.4)   
No risk factors found for CR neoplasia in univariate analysis 
Papatheodori- 
dis et al.182
18 3.2 0 
Dvorchik  
et al.178
169 5.91ȕ  7 CRC  
Not increased risk of CRC post Ltx compared to pre Ltx 
Van de Vrie  
et al.175
17 5.2 4 (2 CRC, 2 CR dysplasia) 
Vera  
et al.194
83 NR 8 CRC. Cum. risk for CRC 5, 10 yrs post Ltx: 14, 17% 
Increased incidence of  CRC in PSC vs. non PSC patients post 
Ltx (5.3% vs.0.6%, p<0.001)  
Risk factors for CRC: CR dysplasia post Ltx, IBD >10 years, 
pancolitis  
Ho  
et al.186
26 4.4 3 (1 CRC, 2 CR dysplasia) 
Hanouneh  
et al195
43 4.6 11 CR dysplasia 
Similar rate of CRN in PSC patients with and without Ltx (34% 
vs.30%, p=0.24) 
Higher rate of CRN in PSC vs. non PSC patients post Ltx (34% 
vs. 0%, p=0.018) 
Risk factor for CRN: CMV infection post Ltx 
#with intact colon at time of Ltx, ȕmean, NR, not reported; NS, not significant; Ltx, liver transplantation;
CR, colorectal; CRC, colorectal cancer; CRN, colorectal neoplasia; RR, relative risk 
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Table 8. Interrater agreement in interpretation of histological findings in terminal ileum and colon (%) 
Feature Term. 
ileum 
Cecum Asc. 
colon 
Transv. 
colon 
Desc. 
colon 
Sigmoid 
colon 
Rectum Interrater 
agreement 
Presence of 
inflammatory 
changes 
100 41 67 68 86 50 65 75 
Chronic active 
inflammation 100 37 67 86 55 60 87 90 
Atrophy 100 23 80 82 48 68 87 91 
Crypt  
distortion 95 45 65 68 91 43 65 72 
Goblet cell  
depletion 90 41 74 50 95 57 48 59 
Interrater 
agreement 97 38 70 71 75 55 70 70 
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9. Errata 
Page 17, third paragraph, line 8: “AIC” should be replaced with “IAC” 
Article II, first page, affiliation no.8: “Section for Transplantation Surgery, Department 
of Transplantation Medicine, Division of Cancer, Surgery and Transplantation, Oslo 
University Hospital, Oslo, Norway” should be replaced with: “Transplantation and 
Liver Surgery Clinic, Helsinki University Hospital, Helsinki, Finland”       

I

II

III

